Does the media favor ARQT or AMPH?

In the previous week, Arcutis Biotherapeutics had 19 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 38 mentions for Arcutis Biotherapeutics and 19 mentions for Amphastar Pharmaceuticals. Arcutis Biotherapeutics' average media sentiment score of 0.73 beat Amphastar Pharmaceuticals' score of 0.62 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 8 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Amphastar Pharmaceuticals 4 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend RGC or AMPH?

Amphastar Pharmaceuticals has a consensus price target of $22.00, indicating a potential upside of 5.87%. Given Amphastar Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Amphastar Pharmaceuticals is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Amphastar Pharmaceuticals 2 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75

Which has stronger earnings & valuation, RGC or AMPH?

Amphastar Pharmaceuticals has higher revenue and earnings than Regencell Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Amphastar Pharmaceuticals $719.89M 1.23 $98.09M $1.69 12.30

Do analysts prefer AMPH or MOR?

Amphastar Pharmaceuticals presently has a consensus price target of $22.00, suggesting a potential upside of 5.87%. Given Amphastar Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Amphastar Pharmaceuticals is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amphastar Pharmaceuticals 2 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75 MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor TRVI or AMPH?

In the previous week, Amphastar Pharmaceuticals had 9 more articles in the media than Trevi Therapeutics. MarketBeat recorded 19 mentions for Amphastar Pharmaceuticals and 10 mentions for Trevi Therapeutics. Amphastar Pharmaceuticals' average media sentiment score of 0.62 beat Trevi Therapeutics' score of 0.16 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amphastar Pharmaceuticals 4 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AMPH or ATAI?

In the previous week, Amphastar Pharmaceuticals had 18 more articles in the media than Atai Beckley. MarketBeat recorded 19 mentions for Amphastar Pharmaceuticals and 1 mentions for Atai Beckley. Amphastar Pharmaceuticals' average media sentiment score of 0.62 beat Atai Beckley's score of 0.50 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amphastar Pharmaceuticals 4 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Atai Beckley 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Amphastar Pharmaceuticals (AMPH) Competitors

$20.78 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$20.76 -0.02 (-0.10%)

As of 07:00 AM Eastern

Compare

AMPH vs. ARQT, RGC, MOR, TRVI, and ATAI

Should you buy Amphastar Pharmaceuticals stock or one of its competitors? MarketBeat compares Amphastar Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Amphastar Pharmaceuticals include Arcutis Biotherapeutics (ARQT), Regencell Bioscience (RGC), MorphoSys (MOR), Trevi Therapeutics (TRVI), and Atai Beckley (ATAI). These companies are all part of the "pharmaceuticals" industry.

How does Amphastar Pharmaceuticals compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

In the previous week, Arcutis Biotherapeutics had 19 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 38 mentions for Arcutis Biotherapeutics and 19 mentions for Amphastar Pharmaceuticals. Arcutis Biotherapeutics' average media sentiment score of 0.73 beat Amphastar Pharmaceuticals' score of 0.62 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	8 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Amphastar Pharmaceuticals	4 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 9.4% of Arcutis Biotherapeutics shares are owned by insiders. Comparatively, 29.6% of Amphastar Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Amphastar Pharmaceuticals has higher revenue and earnings than Arcutis Biotherapeutics. Amphastar Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	8.45	-$16.14M	$0.21	120.43
Amphastar Pharmaceuticals	$719.89M	1.23	$98.09M	$1.69	12.30

Arcutis Biotherapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market.

Arcutis Biotherapeutics presently has a consensus price target of $35.57, indicating a potential upside of 40.65%. Amphastar Pharmaceuticals has a consensus price target of $22.00, indicating a potential upside of 5.87%. Given Arcutis Biotherapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Arcutis Biotherapeutics is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

Amphastar Pharmaceuticals has a net margin of 10.76% compared to Arcutis Biotherapeutics' net margin of 6.15%. Arcutis Biotherapeutics' return on equity of 15.05% beat Amphastar Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	6.15%	15.05%	6.51%
Amphastar Pharmaceuticals	10.76%	14.98%	6.96%

Summary

Arcutis Biotherapeutics beats Amphastar Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Amphastar Pharmaceuticals compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

Regencell Bioscience has a beta of 1.88, indicating that its stock price is 88% more volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market.

0.1% of Regencell Bioscience shares are held by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Amphastar Pharmaceuticals has higher revenue and earnings than Regencell Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Amphastar Pharmaceuticals	$719.89M	1.23	$98.09M	$1.69	12.30

In the previous week, Amphastar Pharmaceuticals had 19 more articles in the media than Regencell Bioscience. MarketBeat recorded 19 mentions for Amphastar Pharmaceuticals and 0 mentions for Regencell Bioscience. Amphastar Pharmaceuticals' average media sentiment score of 0.62 beat Regencell Bioscience's score of 0.00 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Regencell Bioscience	Neutral
Amphastar Pharmaceuticals	Positive

Amphastar Pharmaceuticals has a consensus price target of $22.00, indicating a potential upside of 5.87%. Given Amphastar Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Amphastar Pharmaceuticals is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

Amphastar Pharmaceuticals has a net margin of 10.76% compared to Regencell Bioscience's net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 14.98% beat Regencell Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Amphastar Pharmaceuticals	10.76%	14.98%	6.96%

Summary

Amphastar Pharmaceuticals beats Regencell Bioscience on 11 of the 12 factors compared between the two stocks.

How does Amphastar Pharmaceuticals compare to MorphoSys?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and MorphoSys (NASDAQ:MOR) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Amphastar Pharmaceuticals has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$719.89M	1.23	$98.09M	$1.69	12.30
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

In the previous week, Amphastar Pharmaceuticals had 19 more articles in the media than MorphoSys. MarketBeat recorded 19 mentions for Amphastar Pharmaceuticals and 0 mentions for MorphoSys. Amphastar Pharmaceuticals' average media sentiment score of 0.62 beat MorphoSys' score of 0.00 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Amphastar Pharmaceuticals	Positive
MorphoSys	Neutral

Amphastar Pharmaceuticals has a net margin of 10.76% compared to MorphoSys' net margin of -226.79%. Amphastar Pharmaceuticals' return on equity of 14.98% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	10.76%	14.98%	6.96%
MorphoSys	-226.79%	-694.31%	-22.55%

Amphastar Pharmaceuticals presently has a consensus price target of $22.00, suggesting a potential upside of 5.87%. Given Amphastar Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Amphastar Pharmaceuticals is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are held by insiders. Comparatively, 0.1% of MorphoSys shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Amphastar Pharmaceuticals has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

Summary

Amphastar Pharmaceuticals beats MorphoSys on 13 of the 15 factors compared between the two stocks.

How does Amphastar Pharmaceuticals compare to Trevi Therapeutics?

Trevi Therapeutics (NASDAQ:TRVI) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 15.4% of Trevi Therapeutics shares are owned by company insiders. Comparatively, 29.6% of Amphastar Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Amphastar Pharmaceuticals has higher revenue and earnings than Trevi Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A
Amphastar Pharmaceuticals	$719.89M	1.23	$98.09M	$1.69	12.30

Trevi Therapeutics currently has a consensus target price of $26.75, suggesting a potential upside of 44.52%. Amphastar Pharmaceuticals has a consensus target price of $22.00, suggesting a potential upside of 5.87%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Trevi Therapeutics is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

In the previous week, Amphastar Pharmaceuticals had 9 more articles in the media than Trevi Therapeutics. MarketBeat recorded 19 mentions for Amphastar Pharmaceuticals and 10 mentions for Trevi Therapeutics. Amphastar Pharmaceuticals' average media sentiment score of 0.62 beat Trevi Therapeutics' score of 0.16 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amphastar Pharmaceuticals	4 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Trevi Therapeutics has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market.

Amphastar Pharmaceuticals has a net margin of 10.76% compared to Trevi Therapeutics' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 14.98% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-23.59%	-22.64%
Amphastar Pharmaceuticals	10.76%	14.98%	6.96%

Summary

Amphastar Pharmaceuticals beats Trevi Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Amphastar Pharmaceuticals compare to Atai Beckley?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Atai Beckley (NASDAQ:ATAI) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

In the previous week, Amphastar Pharmaceuticals had 18 more articles in the media than Atai Beckley. MarketBeat recorded 19 mentions for Amphastar Pharmaceuticals and 1 mentions for Atai Beckley. Amphastar Pharmaceuticals' average media sentiment score of 0.62 beat Atai Beckley's score of 0.50 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amphastar Pharmaceuticals	4 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Atai Beckley	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. Comparatively, 28.4% of Atai Beckley shares are held by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are held by company insiders. Comparatively, 19.8% of Atai Beckley shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Amphastar Pharmaceuticals has a net margin of 10.76% compared to Atai Beckley's net margin of -19,019.44%. Amphastar Pharmaceuticals' return on equity of 14.98% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	10.76%	14.98%	6.96%
Atai Beckley	-19,019.44%	-89.79%	-63.58%

Amphastar Pharmaceuticals has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market. Comparatively, Atai Beckley has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market.

Amphastar Pharmaceuticals presently has a consensus target price of $22.00, suggesting a potential upside of 5.87%. Atai Beckley has a consensus target price of $11.06, suggesting a potential upside of 52.50%. Given Atai Beckley's stronger consensus rating and higher probable upside, analysts clearly believe Atai Beckley is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Atai Beckley	1 Sell rating(s)	11 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.27

Amphastar Pharmaceuticals has higher revenue and earnings than Atai Beckley. Atai Beckley is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$719.89M	1.23	$98.09M	$1.69	12.30
Atai Beckley	$4.09M	652.62	-$660.05M	-$2.23	N/A

Summary

Amphastar Pharmaceuticals beats Atai Beckley on 11 of the 17 factors compared between the two stocks.

Get Amphastar Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMPH vs. The Competition

Export

Metric	Amphastar Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$883.98M	$11.85B	$7.00B	$12.99B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	12.30	790.98	270.62	25.05
Price / Sales	1.23	971.35	659.52	107.93
Price / Cash	4.88	15.12	28.89	37.44
Price / Book	1.21	10.38	11.20	6.43
Net Income	$98.09M	$2.78B	$3.45B	$348.10M
7 Day Performance	2.77%	2.82%	3.40%	2.66%
1 Month Performance	11.00%	-0.59%	-0.72%	-0.85%
1 Year Performance	-12.73%	192.60%	77.41%	23.96%

Amphastar Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMPH Amphastar Pharmaceuticals	2.6614 of 5 stars	$20.78 flat	$22.00 +5.9%	-12.7%	$883.98M	$719.89M	12.30	1,976	Trending News Earnings Report Analyst Forecast Gap Up High Trading Volume
ARQT Arcutis Biotherapeutics	4.2661 of 5 stars	$26.03 +0.3%	$34.00 +30.6%	+71.2%	$3.26B	$376.07M	N/A	150	Trending News Earnings Report Analyst Upgrade Analyst Revision Gap Up
RGC Regencell Bioscience	0.1497 of 5 stars	$6.05 -1.3%	N/A	-61.3%	$2.99B	N/A	N/A	10
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
TRVI Trevi Therapeutics	3.315 of 5 stars	$18.75 +4.7%	$24.91 +32.8%	+149.5%	$2.66B	N/A	N/A	20	Earnings Report Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AMPH) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amphastar Pharmaceuticals (AMPH) Competitors

AMPH vs. ARQT, RGC, MOR, TRVI, and ATAI

How does Amphastar Pharmaceuticals compare to Arcutis Biotherapeutics?

Summary

How does Amphastar Pharmaceuticals compare to Regencell Bioscience?

Summary

How does Amphastar Pharmaceuticals compare to MorphoSys?

Summary

How does Amphastar Pharmaceuticals compare to Trevi Therapeutics?

Summary

How does Amphastar Pharmaceuticals compare to Atai Beckley?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMPH vs. The Competition

Amphastar Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amphastar Pharmaceuticals (AMPH) Competitors

AMPH vs. ARQT, RGC, MOR, TRVI, and ATAI

How does Amphastar Pharmaceuticals compare to Arcutis Biotherapeutics?

Does the media favor ARQT or AMPH?

Do institutionals & insiders have more ownership in ARQT or AMPH?

Which has preferable earnings & valuation, ARQT or AMPH?

Which has more risk & volatility, ARQT or AMPH?

Do analysts prefer ARQT or AMPH?

Is ARQT or AMPH more profitable?

Summary

How does Amphastar Pharmaceuticals compare to Regencell Bioscience?

Which has more risk & volatility, RGC or AMPH?

Do institutionals & insiders have more ownership in RGC or AMPH?

Which has stronger earnings & valuation, RGC or AMPH?

Does the media prefer RGC or AMPH?

Do analysts recommend RGC or AMPH?

Is RGC or AMPH more profitable?

Summary

How does Amphastar Pharmaceuticals compare to MorphoSys?

Which has higher valuation & earnings, AMPH or MOR?

Does the media prefer AMPH or MOR?

Is AMPH or MOR more profitable?

Do analysts prefer AMPH or MOR?

Do institutionals and insiders hold more shares of AMPH or MOR?

Which has more risk and volatility, AMPH or MOR?

Summary

How does Amphastar Pharmaceuticals compare to Trevi Therapeutics?

Do insiders and institutionals hold more shares of TRVI or AMPH?

Which has stronger valuation & earnings, TRVI or AMPH?

Do analysts rate TRVI or AMPH?

Does the media favor TRVI or AMPH?

Which has more volatility & risk, TRVI or AMPH?

Is TRVI or AMPH more profitable?

Summary

How does Amphastar Pharmaceuticals compare to Atai Beckley?

Does the media prefer AMPH or ATAI?

Do institutionals and insiders have more ownership in AMPH or ATAI?

Is AMPH or ATAI more profitable?

Which has more risk & volatility, AMPH or ATAI?

Do analysts recommend AMPH or ATAI?

Which has better earnings and valuation, AMPH or ATAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMPH vs. The Competition

Amphastar Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools